Immune Thrombocytopenia

Cindy Neunert, MS MSCS
Professor, Pediatrics
Section Head, Pediatric Hematology
CUIMC Columbia University Irving Medical Center

Financial Disclosures

- Advisory Board
  - Janssen, UK ITP Association, Australian ITP Association
- Honorarium
  - Novartis, Sanofi, Argenx, Sobi, Lilly
- Royalties
  - Up to Date
- Research Funding
  - Novartis

Objectives


1. Review the pathophysiology of ITP
2. Discuss the diagnosis of ITP
3. Outline first- line management
4. Provide an overview of second- line treatment strategies
5. Highlight third-line agents and novel agents in development

Epidemiology and Pathophysiology

Module 1

Immune Thrombocytopenia

- An autoimmune disorder
  - Isolated thrombocytopenia: platelet count < 100 × 10^9/L
  - The absence of other causes or disorders that may be associated with thrombocytopenia
  - Remains a diagnosis of exclusion
- Increased risk of bleeding
  - Bleeding is very heterogeneous
- Can be primary or secondary




SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome; CVID, common variable immune deficiency; CLL, chronic lymphocytic leukemia; APLS, autoimmune lymphoproliferative syndrome; post-tx, post-bone marrow or solid organ transplantation

Cuker A. *Hematology Am Soc Hematol Educ Program*. 2010
Rodeghiero F, et al. *Blood.* 2009

Epidemiology

Annual incidence: 1.6-3.9 per 100,000 person-years




= Females

= Males

*Statistically significant differences among males and females (α = 5%)


Moulis G, et al. *Blood. 2014*




Despotovic. Hematology Am Soc Hematol Educ Program 2018

Pathogenesis

- Dr. Harrington and Dr. Hollingsworth in 1950
  - Injected blood from a patient with ITP
  - Developed severe thrombocytopenia
  - Bone marrow showed normal number of megakaryocytes






"This experiment, one of the most important ever to be performed in the field of hematology….changed the meaning of the "I" in ITP from idiopathic to immune"

- Schwartz, 2007, NEJM


Harrington et al. J Lab Clin Med 1951

Pathogenesis: Then…..



Wei and Jackson Nat Med 2008

Pathogenesis Now….




Al-Samkari H, Kuter DJ. Semin Thromb Hemost.2020

Diagnosis
Module 2

Diagnosis

- **A diagnosis of exclusion:**
  - Defined as a platelet count of less than 100 × 10^9/L
  - Absence of red and white cell abnormalities
  - Anemia if significant bleeding present
  - Pay attention to red cell indices



- Peripheral blood smear
  - Few large to normal platelets present
  - No red or white cell abnormalities
- HCV and HIV testing is recommended for all patients
- Bone marrow examination
  - Not necessary in patients presenting with typical ITP
  - Age and failure of response to standard therapy are a debated factors

ITP: Clinical Manifestations

- Bleeding
  - Substantial inter-individual variation in bleeding phenotype
  - Mucocutaneous bleeding is most common manifestation
  - Spontaneous intracranial hemorrhage (ICH) is rare, especially when platelet count is >20 x 10^9/l
  - Advanced age, prior bleeding, anti-platelet/anticoagulants are independent risk factors
- Impact on health-related quality of life (HRQoL)
  - Fatigue, worry about bleeding, reduced activities
- Possible increase in thrombotic events


ITP Physical Examination











Terminology

- Newly Diagnosed ITP: ≤ 3 months
- Persistent ITP: 3-12 months
- Chronic ITP: > 12 months
- Should not determine treatment
- Updated terminology underway

Rodeghiero et al. Blood, 2009

Treatment

- The goal of treatment is to achieve normal hemostasis, not to reach a normal platelet count
- Additional considerations beyond the platelet count should be considered:
  - Age
  - Upcoming surgery
  - Comorbidities associated with a risk of bleeding
  - Anti-platelet medications or anticoagulation
  - Social concerns about distance from the hospital, ability to follow-up, etc
  - Additional symptoms such as fatigue and assessment of health-related quality of life

Initial/Emergency Treatment

Module 3

Upfront Management of ITP

	Dose	Time to Response	Side Effects
Observation and Education	Time	1 week - indefinite	Bleeding
Corticosteroids	**Adults:** Prednisone (0.5 to 2.0 mg/kg/day) or dexamethasone (40 mg/day for 4 days) **Children:** 2-4 mg/kg PO divided BID for 5-7 days	3-4 days	Mood changes Hypertension Hyperglycemia Gastritis
IVIG	0.8-1.0 gm/kg IV for one dose Up to 2gm/kg max	24-48 hours	Infusion reaction Headache/Aseptic meningitis Thrombosis FDA Black box warning for renal failure
Anti-D Immunoglobulin (WinRho)	50-75 mcg/kg IV for one dose	24-48 hours	Hemolysis (2.0 gram decrease in Hgb) FDA Black box warning for fatal intravascular hemolysis

2019 ASH Guidelines: Adult Newly Diagnosed

Recommendation	Population	Intervention	Comparator	Strength	Certainty in the evidence
1a	Platelet Count < 30 x 10^9/l Asymptomatic or minor bleeding	Corticosteroids	Observation	Conditional	Very low
1b	Platelet Count ≥ 30 x 10^9/l Asymptomatic or minor bleeding	Corticosteroids	Observation	Strong	Very low
2a	Platelet Count < 20 x 10^9/l Asymptomatic or minor bleeding	Inpatient (new patient)	Outpatient (established patient)	Conditional	Very low
2b	Platelet Count ≥ 20 x 10^9/l Asymptomatic or minor bleeding	Inpatient	Outpatient	Conditional	Very low
3	Requiring corticosteroids	Prolonged corticosteroids	Short course of corticosteroids	Strong	Very low
4	Requiring corticosteroids	Prednisone	Dexamethasone	Conditional	Very low
5	Requiring treatment	Corticosteroids	Corticosteroids plus rituximab	Conditional	Very low

Neunert et al. Blood Adv, 2019

ASH Guidelines: Adult ITP Newly Diagnosed

- Also carried forward recommendations from the 2011 ASH Guidelines:
  - IVIG be used with corticosteroids when a more rapid increase in platelet count is required (grade 2B)
  - Either IVIG or anti-D (in appropriate patients) be used as a first-line treatment if corticosteroids are contraindicated (grade 2C)
  - If IVIG is used, the dose should initially be 1 g/kg as a 1-time dose; this dosage may be repeated if necessary (grade 2B)

Good Practice Statement

- The treating physician should ensure the patient is adequately monitored for potential corticosteroid side effects regardless of the duration or type of corticosteroid selected. This includes close monitoring for hypertension, hyperglycemia, sleep and mood disturbances, gastric irritation or ulcer formation, glaucoma, myopathy, and osteoporosis.
- Given the potential impact of corticosteroids on mental health, the treating physician should conduct an assessment of health-related quality of life (depression, fatigue, mental status, etc.) while patients are receiving corticosteroids.

Neunert et al. Blood Adv, 2019

Prednisone or High Dose Dexamethsone

- Primary aim: 6-month response rates
- Response at 6 months did not vary
  - Overall response 54% vs 43%
  - Complete response 37% vs 21%
- Increase in OR by day 14 with dexamethasone
- No effect of high cumulative dose
- Adverse event rates:
  - 24 per 100 patients in the dexamethasone group
  - 46 per 100 patients in the prednisone group

Mithoowani et al. Lancet Haematolo 2016

2026 ASH Guidelines: Adult Newly Diagnosed

Recommendation	Population	Intervention	Comparator	Strength	Certainty in the evidence
1a	Platelet Count < 30 x 10^9/l Asymptomatic or minor bleeding	Corticosteroids	Observation	Conditional	Very low
1b	Platelet Count ≥ 30 x 10^9/l Asymptomatic or minor bleeding	Corticosteroids	Observation	Strong	Very low
2a	Platelet Count < 20 x 10^9/l Asymptomatic or minor bleeding	Inpatient (new patient)	Outpatient (established patient)	Conditional	Very low
2b	Platelet Count ≥ 20 x 10^9/l Asymptomatic or minor bleeding	Inpatient	Outpatient	Conditional	Very low
3	Requiring corticosteroids	Prolonged corticosteroids	Short course of corticosteroids	Strong	Very low
4	Requiring corticosteroids	Prednisone	Dexamethasone	Conditional	Very low
5	Requiring treatment	Corticosteroids or corticosteroids plus MMF	**Corticosteroids plus rituximab or Corticosteroids plus TPO-RA**	Conditional	Very low

2019 ASH Guidelines: Pediatric Newly Diagnosed

Recommendation	Population	Intervention	Comparator	Strength	Certainty in the evidence
10a/b	All newly diagnosed	Inpatient	Outpatient	Conditional	Very low
11	No or mild bleeding	Corticosteroids	Observation	Conditional	Very low
12	No or mild bleeding	IVIg	Observation	Strong	Moderate
13	No or mild bleeding	Anti-D immunoglobulin	Observation	Strong	Moderate
14	Non-life-threatening mucosal bleeding or impaired HRQoL	Prolonged corticosteroids	Short course corticosteroids	Strong	Very low
15	Non-life-threatening mucosal bleeding or impaired HRQoL	Prednisone	Dexamethasone	Conditional	Very low
16	Non-life-threatening mucosal bleeding or impaired HRQoL	Corticosteroids	Anti-D immunoglobulin	Conditional	Low
17	Non-life-threatening mucosal bleeding or impaired HRQoL	Anti-D immunoglobulin	IVIg	Conditional	Low
18	Non-life-threatening mucosal bleeding or impaired HRQoL	Corticosteroids	IVIg	Conditional	Low

Neunert et al. Blood Adv, 2019

PINES Trial


Could treatment with eltrombopag during the newly diagnosed phase of ITP lead to a more sustained and durable response?

- **Primary Objective:** To determine if the proportion of patients with a platelet response is significantly greater in patients with newly diagnosed ITP treated with eltrombopag than those treated with standard first-line treatments

- **Primary Endpoint:** Platelet response (binary), defined as ≥ 3 of 4 platelet counts >50 $x10^9$/L during weeks 6-12 of therapy, without rescue therapy

Shimano, et al. *JAMA* 2025.

PINES Trial



Shimano, et al. *JAMA* 2025.

Table 1. Patient Characteristics in the PINES Trial

	Eltrombopag (n = 78)	Standard therapy (n = 40)
Age at enrollment, median (IQR), y	7.9 (4.3-11.8)	8.7 (4.3-12.6)
Sex, No. (%)		
Female	42 (54)	18 (45)
Male	36 (46)	22 (55)
Race and ethnicity, No. (%)[a]		
Asian	3 (4)	3 (9)
Black	4 (6)	3 (9)
Hispanic or Latino	15 (21)	11 (29)
Not Hispanic or Latino	56 (79)	27 (71)
>1 Race	3 (4)	1 (3)
White	59 (86)	26 (79)
Treatment status at enrollment, No. (%)		
No prior therapy received and within 10 d of diagnosis	29 (37)	15 (38)
Prior treatment failure	49 (63)	25 (63)
Under observation for >10 d (no prior therapy received)	10 (13)	12 (30)
Received intravenous immunoglobulin[b]	23 (29)	8 (26)
Received steroids[b]	21 (27)	5 (13)
Received anti-D immunoglobulin[b]	1 (1)	0
Primary indications for treatment, No. (%)[c]		
Bleeding symptoms	54 (69)	24 (60)
Severity of thrombocytopenia	47 (60)	21 (53)
Baseline activity level is high	43 (55)	19 (48)
Time from diagnosis to study enrollment, median (IQR), d	14 (1-26)	16 (1-52)
Bleeding score at enrollment, median (IQR)		
Buchanan-Adix Scale[d]	3 (2-3)	2 (1-3)
World Health Organization Scale[e]	2 (1-2)	1 (1-2)
Parent-proxy-reported Kids' ITP Tool score, mean (SD)[f]	71.5 (13.5)	76.2 (15.2)
Platelet count at enrollment, median (IQR), × 10^9/L	4 (3-10)	8 (3.5-17.0)
Type of study treatment received, No. (%)		
Eltrombopag	78 (100)	
Prednisone		29 (73)
Intravenous immunoglobulin		11 (28)
Anti-D immunoglobulin		0

Abbreviation: PINES, Pediatric ITP Newly Diagnosed Patients Eltrombopag vs

[b] Patients could have received 2 or fewer of these 3 treatments prior to study entry

PINES Trial: Primary Endpoint


Primary endpoint:
≥3 of 4 platelet counts >50 x10^9/L during weeks 6-12 without rescue treatment

2nd Interim Analysis
N = 108 (66.7% of planned 162 enrolled)

Responder	Eltrombopag (N=71)	Standard Therapy (N=37)
Yes	45 (63%)	13 (35%)
No	26 (37%)	24 (65%)

p-value = 0.0054, z-score = 2.78

Total Enrolled Cohort
N = 118



PINES Trial showed benefit of eltrombopag in children with newly diagnosed ITP


Shimano, et al. *JAMA* 2025.

PINES Trial: Secondary Outcomes

- **Need for rescue therapy:**
  - Eltrombopag arm (14/78; 18%)
  - Standard arm (15/39; 46%)
- **Bleeding**:
  - Proportion with a high bleeding score was similar at all timepoints
- **Composite endpoint:** platelets >30x10^9/L, ≥2-fold increase from baseline, and no bleeding
  - Earlier in the standard treatment group versus the eltrombopag group (14 days vs 21 days), p=0.02
  - Higher proportion of maintained this in the eltrombopag group at week 12 assessment (66% vs 44%), p=0.03
- **Health-Related Quality of Life:**
  - Improved in both arms
- **No new safety signals**

Shimano, et al. *JAMA* 2025.

Subsequent Treatment
Module 4



Rituximab


Splenectomy and Fostamatinib

Thrombopoeitin Receptor Agonists (TPO-RAs)

Wei and Jackson Nat Med 2008

Splenectomy


- Response:
  - Remission in 2/3 of patients
- Need to vaccinate against encapsulated organisms
  - Monitor titers and revaccinate for pneumococcus and HIB every 3-5 years
  - Life-long fever precautions and antibiotic prophylaxis
- Potential Thrombosis Risk



Ghanima W et al. Blood 2012; Stasi R, Provan D. Mayo Clin Proc 2004, Crary and Buchanan Blood 2009


Rituximab

- Early remission rates
  - Adults: 57-63%
  - Pediatric: 57% -68%
- Sustained remission rates remain lower



Arnold et al. Int Med 2007;Patel et al Blood 2012; Liang et al PloS one 2012

Thrombopoietin



http://thelancet.com/cms/attachment/2001001856/2003729871/gr1_lrg.jpg

- Prevents megakaryocyte apoptosis
- Induces mobilization of stem cells
- Megakaryocyte proliferation/differentiation
- JAK/STAT activation

Gernsheimer, The Oncologist 2009

TPO-RAs

- Romiplostim, eltrombopag, avathrombopag, and lusutrombopag
  - Discontinuation results in thrombocytopenia
  - Reports suggest no cross-resistance
- Increase platelet count, decrease bleeding, reduce additional medications, and improve health-related quality of life (HRQoL)
- Sustained drug free response following use
  - Immune tolerance?
  - Restore T and B regulatory cells

Polverelli Brit J of Haematol 2013; D'Arena Blood 2013; Ghadaki et al. Transfusion 2013

TPO-RAs

- Bone marrow reticulin and transformation
  - EXTEND study: No grade 3 reticulin, symptoms of bone marrow dysfunction, or blast counts >3%

- Thromboembolic events
  - Event rate of 3.17-4.16 per 100 patient years
  - No increased risk in meta-analysis of romiplostim

- Eltrombopag hepatotoxicity
  - 10% of patients had drug induced liver insufficiency
  - Reversible with drug discontinuation

Saleh et al. Blood 2013; Kuter et al. British journal of haematology 2013; Cines et al. Haematologica 2017


TPO-RAs

- STOPAGO: a nationwide prospective multicenter2 year interventional study

- 49 patients
  - Persistent (n=2) or chronic (n=47)
  - Median age of 58.5 years IQR (41 to 73)

- An number of patients with chronic ITP demonstrated a sustained off-treatment remission after discontinuation
  - Initially achieve a stable CR

- Relapses are mainly observed within the first weeks after discontinuation




Mahevas M, et al. ASH 2021. 583.
Newland AC, et al. ASH 2011 3157.

Fostamatinib

- Phase III clinical studies (n=146)
  - 2 randomized controlled trials and 1 open-label extension study
  - Dose: 100mg BID PO and increased to 150mg BID
- Overall response (n=101): 43% versus 14% placebo
  - Second-line therapy: 25/32 (78%) had an overall platelet response
- The most commonly reported AEs
  - Diarrhea, hypertension, nausea, vomiting, dizziness, and transaminitis
  - Resolved or were managed by dose reduction or dose interruption

Busell et al. Am J Haem 2018

Fostamatinib



Open label extension study: 17% had a stable response

Busell et al. Am J Haem 2018, Busell et al. Am J Haem 2019

Durable Response

TPO-RAs: Romiplostim
38% versus 0%
61% versus 5%
PC ≥ 50 x 10^9/l for ≥ 6 of the last 8 weeks

TPO-RAs: Eltrombopag
60% versus 10%
PC ≥ 50 - 400 x 10^9/l for ≥ 6 of the last 8 weeks


TPO-RAs: Avatrombopag
34.4% versus 0%
PC ≥ 50 x 10^9/l for ≥ 6 of the last 8 weeks

Rituximab
46.8% versus 32.5%
PC ≥ 100 x 10^9/l at 24 weeks

Fostamatinib
18% versus 2%
PC ≥ 50 x 10^9/l for ≥ 4 of 6 biweekly counts weeks 14-24

Splenectomy
53%
PC ≥ 30 x 10^9/l and at least doubling at 6 mths

2026 ASH Guidelines



2019 ASH Pediatric ITP Guidelines

In children with ITP who have non-life-threatening mucosal bleeding and/or diminished health-related quality of life and do not response to first-line treatment:

***Suggests* the use of TPO-RAs rather than rituximab.**

***Suggests* TPO-RAs rather than splenectomy.**

***Suggests* rituximab rather than splenectomy.**

All conditional recommendations based on very low certainty in the evidence of effects.

Good Practice Statement

- The choice of second-line treatment should be individualized based on duration of ITP, frequency of bleeding episodes requiring hospitalization or rescue medication, comorbidities, adherence, medical and social support networks, patient values and preferences, cost, and availability.
- Patient education and shared decision-making are encouraged.
- If possible, splenectomy should be delayed for as long as possible after diagnosis because of the potential for spontaneous remission.

Neunert et al. Blood Adv, 2019

Additional and Novel Therapies


Module 5

Other ITP Therapies

Drug	No. of studies	Response within 7 days		Response within 1 month		Durable Response		Remission	
		Unweighted	Weighted (95% CI)	Unweighted	Weighted (95% CI)	Unweighted	Weighted (95% CI)	Unweighted	Weighted (95% CI)
Azathioprine	3	_____	_____	27% 21/77 N=2	30% (1-95%) N=2	59% 55/94 N=2	58% (45-70%) N=2	40% 21/53 N=1	NA
Cyclophosphamide	4	_____	_____	34% 17/50 N=2	34% (3-91%) N=2	58% 46/80 N=2	57% (46-68%) N=2	48% 19/40 N=2	45% (25-67%) N=2
Cyclosporine A	5	21% 7/34 N=2	21% (10-39%) N=2	48% 52/109 N=4	48% (38-58%) N=4	32% 22/69 N=3	32% (21-47%) N=3	27% 21/79 N=3	27% (18-37%) N=3
Danazol	9	_____	_____	33% 191/582 N=7	38% (26-52%) N=7	59% 137/231 N=5	57% (38-74%) N=5	5% 1/21 N=1	NA
Dapsone	5	_____	_____	50% 133/265 N=5	50% (39-60%) N=5	22% 33/147 N=3	21% (7-47%) N=3	13% 12/89 N=2	13% (6-27%) N=2
Mycophenolate mofetil	4	14% 7/50 N=2	15% (7-28%) N=2	48% 48/100 N=4	48% (37-60%) N=4	61% 43/71 N=3	61% (49-71%) N=3	23% 16/71 N=3	22% (8-48%) N=3
Vinca alkaloids	14	71% 67/95 N=3	71% (52-85%) N=3	66% 268/407 N=13	65% (57-72%) N=13	33% 60/182 N=6	28% (13-50%) N=6	25% 52/206 N=5	26% (20-33%) N=5


Neunert et al. Blood Adv, 2019

New/Novel Therapies



Wei and Jackson Nat Med 2008;14:720-721

Rilzabrutinib




B cells, plasma cells	Monocyte, macrophage	Mast cells, basophils	Neutrophils	T cells
Blocks B-cell receptor Inhibits plasma cell differentiation and antibody production	Blocks IgG-mediated FcgR activation, phagocytosis, inflammatory mediators	Blocks IgE-mediated FceR activation and degranulation	Inhibits activation, adhesion, recruitment, oxidative burst	No effect
BTK inhibition				

IgG, immunoglobulin G

Kuter DJ, et al. *Ther Adv Hematol*. 2023, Langrish CL, et al. *J Immunol*. 2021.

Rilzabrutinib: LUNA3

400mg BID versus placebo



Durable Response:
23% of patients receiving rilzabrutinib compared to 0% in the placebo


Overall Platelet Response:
65% with rilzabrutinib and 33% with placebo

Most common side effect is gasterointestinal and usually resolves with time

Ongoing pediatric trial

Kuter DJ, et al. *Blood* 2025.

Anti-CD38 Antibodies




Daratumumab and Mezagitamab both with open adult trials
Administered IV or SQ weekly

Mezagitamab:
In adult Phase 2 trial:
- 600mg SQ for 8 weeks
- Platelet response was seen in 91% of patients in the mezagitamab arm and 23% of the placebo arm

Daratumumab: Phase 2, prospective, one-arm and open clinical study to assess safety and efficacy:
- **age ≥ 6 years**
- primary ITP for ≥ 3mths months
- platelet count of <30 X 10^9/L

Martínez-Carballeira D, et al. *Hematol Rep*. 2024, Kuter et al. NEJM 2026, Strüßmann T, et al. *Ann Hematol*. 2023.

Anti-CD20 Antibodies



Anti-CD20 Antibody

Obinutuzumab: sustained responses in 5 adult patients with relapsed or refractory ITP


- 3 complete and 2 partial responses
- 1 mild infusion reaction and 3 manageable infections during the median 9-month follow-up

Obinutuzumab: Phase 2, prospective, one-arm and open clinical study to assess safety and efficacy:

- Patients aged **12-18 years**
- Primary ITP
- Platelet count of <30 X 10^9/L

Martínez-Carballeira D, et al. *Hematol Rep*. 2024;

BAFF Receptor Inhibition



BAFF Receptor Inhibition

Ianalumab:

VAYHIT1: Ianalumab + corticosteroids upfront

VAYHIT2: Ianalumab + eltrombopag

- Longer time to treatment failure

VAYHIT3: Second line treatment

- A short course of ianalumab was effective and well tolerated
- Nearly half (44%) of the patients achieved a response
- More than half (56%) of responders maintained a stable response at 6 months
- No new safety signals

Planned pediatric clinical study

Cuker A, et al. *NEJM* 2025.

2025 Clinical Trial Update in Immune Thrombocytopenia

Efgartigimod


Neonatal Fc Receptor Antagonist



Status: Completed Phase 3
ADVANCE IV Study (Intravenous): Positive
ADVANCE SC Study (Subcutaneous): Negative

Rilzabrutinib


Bruton's Tyrosine Kinase Inhibitor



Status: Completed Phase 3 (Adults)
LUNA 3 Study (Adult Portion): Positive
LUNA 3 Study (Pediatric Portion): Ongoing

Ianalumab

BAFF Receptor Antagonist



Status: Ongoing Phase 2 and Phase 3
VAYHIT1 (1st Line + Steroids): Ongoing
VAYHIT2 (2nd Line + Eltrombopag): Ongoing
VAYHIT3 (Later line): Ongoing

Povetacicept

BAFF and APRIL Antagonist



Status: Ongoing Phase 2
RUBY-4 Study (Basket Trial): Ongoing

Anti-CD38 Antibodies


Mezagitamab, Daratumumab, CM313



Status: Completed and Ongoing Phase 2
TAK-079-1004 (Mezagitamab, SC): Positive
DART Study (Daratumumab, SC): Ongoing
2022-CM313-ITP (CM313, IV): Positive

Complement Inhibitors

Iptacopan, Sutimlimab



Status: Completed Phase 1 and Phase 2
CLNP023L12201 (Iptacopan): Completed
Phase 1 Study of Sutimlimab: Positive

Novel SYK Inhibitors

Sovleplenib and Cevidoplenib



Status: Completed Phase 2 and Phase 3
2018-523-00CH1 Study (Sovleplenib Phase 2): Positive
ESLIM-1 (Sovleplenib Phase 3): Positive
OSCO-P2101 Study (Cevidoplenib Phase 2): Positive

Conclusions:

- Many agents in development target pathophysiologic mechanisms not previously targeted by agents in current use
- These agents represent promising options for patients with disease refractory to current therapies and may allow for more personalized treatment in the future
- New approaches to ITP clinical trials are in motion, including treatment with novel agents in combination with established agents early in disease to modify the disease course

Al-Samkari. *Am J Haematol 2024.*

Conclusions

- ITP remains a diagnosis of exclusion
- Management of ITP in both adults and children is based on the clinical symptoms and consideration of additional risk factors
- There are a lack of randomized trials to guide management
- Exciting new drug development may provide treatment options for the most refractory patients

Case Based Questions

Case 1: New thrombocytopenia

26-year-old female seen by her PCP for a routine yearly checkup:

Complete blood count with differential is normal except for a low platelet count of 50 x 10^9/L. She is asymptomatic without any concerns for bleeding.

Physical Examination: No additional findings on exam

Labs:

- HIV, Hep C and B are normal
- Metabolic panel is unremarkable
- Peripheral blood smear shows no platelet clumping or other morphologic abnormalities

Past Medical History: None

Medications: None

Diagnosis: ITP

As her hematologist, what is the next best step for treating this patient?

A. Initiate low dose prednisone at 20mg/day for ‘mild ITP’
B. Discharge the patient back to her PCP for annual lab work
C. Monitor her labs closely
D. Initiate dexamethasone at 40mg/day x 4 days for a quick response

Neunert et al. Blood Adv, 2019; Provan et al. Blood Adv, 2019

Case 1, Continued:

- Her platelet count continues to be around 50 x 10^9/L on monthly monitoring until 3 months later when she calls your office because of ‘blood blisters’ appearing suddenly in her mouth, large skin bruises on her arms and legs, and menorrhagia.
- She also reports feeling more fatigued than usual.
- Her platelet count is 15 x 10^9/L and her hemoglobin has dropped to 10 g/dL

How should you manage her severe ITP with bleeding?

A. Observation since she has an acute viral illness that will self resolve
B. Initiate low dose prednisone at 20mg/day and avatrombopag
C. Admit her to the hospital and start treatment with corticosteroids
D. Start eltrombopag for initial episode of symptomatic severe ITP

Neunert et al. Blood Adv, 2019; Provan et al. Blood Adv, 2019; Mithoowani et al. Lancet Haematolo 2016

Case 1, Continued:

- It has now been 6 months since you initiated treatment for ITP.
- She has responded to combination therapy but has now had a decline in her platelet count again and is having heavy menstrual bleeding.
- She was subsequently treated with a course of dexamethasone, but this only temporarily increased her platelet count.
- She presents to your office to discuss options to prevent another relapse

Which of these statements is false about the next best course of action?

A. Rituximab has a durable effect on preventing ITP recurrences for 5 years in 75% with relapsed ITP

B. Either thrombopoietin receptor agonist is an acceptable option for treatment of ITP after failure of corticosteroid therapy

C. Splenectomy is effective for treatment of relapsed ITP, but carries increased risk of long term infections and thrombosis

D. Several immunosuppressive agents like mycophenolate mofetil and azathioprine have activity in adults with relapsed ITP, but are usually reserved for patients who fail second- line therapies

Neunert et al. Blood Adv, 2019; Provan et al. Blood Adv, 2019; Arnold et al. Int Med 2007;Patel et al Blood 2012; Liang et al PloS one 2012

Case 2:

6-year-old male presents with a 24-hour history of bruising and petechiae with no additional bleeding. He was previously healthy and there is no family history of thrombocytopenia.

Physical examination: Scattered petechiae and several bruises to the arms and legs . There is no lymphadenopathy or hepatosplenomegaly

Labs:

- Complete blood count with a platelet count of 8 x 10^9/L and is otherwise normal
- Peripheral blood smear shows a few large platelets and no other morphologic abnormalities

Medications: None

Diagnosis: **ITP**

As his hematologist, what is the next best step for treating this patient?

A. Initiate prednisone at 20mg/day
B. Discharge the patient back to her PCP for annual lab work
C. Admit to hospital for IVIg
D. Monitor his labs and educate the family about potential bleeding symptoms

Neunert et al. Blood Adv, 2019; Provan et al. Blood Adv, 2019

Case 2: Continued

- The child's mother calls you and in addition to a few bruises she notices "wet purpura" in the his mouth.
- She also states that he had a 10 minute episode of epistaxis the day before that stopped with pressure.
- His platelet count is 6 x 10^9/L
- You decide to treat him with corticosteroids while awaiting approval for a TPO-RA

What dose of corticosteroids should be prescribed?

A. Dexamethasone 0.6mg/kg/day (maximum of 40 mg/day) for 4 days
B. Prednisone 2-4mg/kg/day (maximum 120 mg daily) for 5-7 days
C. Prednisone 0.5-1.0 mg/kg/day for 10 days
D. Prednisone 2-4mg/kg/day for 21 days with a taper based on platelet count

Neunert et al. Blood Adv, 2019; Provan et al. Blood Adv, 2019

Case 2: Continued

- 6 months later the child continues to have a platelet count of 20 x10^9/L
- He responds to IVIg every 3 weeks
- He has had a decline in response to Anti-D immunoglobulin and corticosteroids
- Suffers from recurrent epistaxis and as a result is being sent home from school
- Parents are wondering whether the child can return to soccer practice and report that his quality of life suffering

What treatment should you offer the child now?

A. Continue with IVIg every 3 weeks
B. Splenectomy
C. Romiplostim in combination with corticosteroids
D. Discuss treatment with either rituximab or a thrombopoietin receptor agonist
E. No therapy

Neunert et al. Blood Adv, 2019; Provan et al. Blood Adv, 2019